CYANOISOQUINOLINE COMPOUNDS (VERSIONS), PHARMACEUTICAL COMPOSITION BASED THEREON, HYPOXIA-INDUCIBLE FACTOR (HIF) HYDROXYLASE INHIBITING METHOD AND METHOD OF TREATING AND/OR PREVENTING HIF-ASSOCIATED CONDITION AND/OR ERYTHROPOIETIN-AND/OR ANAEMIA-ASSOCIATED CONDITION Russian patent published in 2012 - IPC C07D217/26 C07D405/12 C07D413/14 C07D417/12 A61K31/472 A61K31/4725 A61P7/06 

FIELD: chemistry.

SUBSTANCE: present invention relates to novel cyanoisoquinoline derivatives of formula I , where R is selected from a group comprising hydrogen and C₁-C₁₀ alkyl, R¹, R², R³ and R⁴ are independently selected from a group comprising hydrogen, halogen, hydroxy, C₁-C₁₀ alkyl, substituted with 1-3 halogen atoms or C₆-C₁₄ acryl, C₆-C₁₄ aryl, -OR⁷, -SR⁷ and -SO₂R⁷, where R⁷ is selected from a group comprising C₁-C₁₀ alkyl, C₁-C₁₀ alkyl substituted with C₆-C₁₄ aryl, C₃-C₁₀ cycloalkyl, C₆-C₁₄ aryl and C₇-C₈ heteroaryl containing 1-2 heteroatoms selected from a group comprising N, O and S, where C₆-C₁₄ aryl and C₇-C₈ heteroaryl are optionally substituted with 1-3 substitutes selected from a group comprising halogen, C₁-C₆ alkoxy, C₁-C₁₀ alkyl, C₁-C₆ dialkylamino and C₄ heterocyclyl containing 2 heteroatoms selected from a group comprising nitrogen and oxygen, and R⁵ and R⁶ are independently selected from a group comprising hydrogen and C₁-C₃ alkyl, or pharmaceutically acceptable salts thereof. The invention also relates to novel cyanoquinoline derivatives of formula II , where R³¹, R³², R³³ and R³⁴ are independently selected from a group comprising hydrogen, hydroxy, halogen, C₁-C₁₀ alkyl substituted with 1-3 halogen atoms or with C₆-C₁₄ aryl, C₆-C₁₄ aryl, -OR³⁷, -SR³⁷ and -SO₂R³⁷, where R³⁷ is selected from a group comprising C₁-C₁₀ alkyl, C₁-C₁₀ alkyl substituted with C₆-C₁₄aryl, C₃-C₁₀ aryl, C₇-C₈ heteroaryl containing 1-2 heteroatoms selected from a group comprising N, O and S, where C₆-C₁₄ aryl and C₇-C₈ heteroaryl are substituted with 1-3 substitutes selected from a group comprising halogen, C₁-C₆ alkoxy, C₁-C₁₀ alkyl, C₁-C₆ dialkylamino C₄ heterocyclyl containing 2 heteroatoms selected from a group comprising nitrogen and oxygen, R³⁵ denotes hydrogen or methyl, or pharmaceutically acceptable salts thereof. The invention also relates to specific cyanoisoquinoline compounds, a pharmaceutical composition based on the compound of formula I, a hypoxia-inducible factor (HIF) hydroxylase inhibiting method, a method of treating, preventing or slowing down development of a condition associated with hypoxia-inducible factor (HIF), a condition associated with erythropoietin (EPO), anaemia, based on use of the compound of formula I.

EFFECT: obtaining novel cyanoisoquinoline compounds having useful biological properties.

42 cl, 1 tbl, 54 ex